Viral Vector and Plasmid DNA Manufacturing Market (By Vector Type: AAV, Lentivirus; By Workflow, By Application; By End-use; By Disease) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Viral Vector and Plasmid DNA Manufacturing Market 

5.1. COVID-19 Landscape: Viral Vector and Plasmid DNA Manufacturing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type

8.1. Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2024-2033

8.1.1. Adenovirus

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Retrovirus

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Adeno-Associated Virus (AAV)

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Lentivirus

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Plasmids

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Viral Vector and Plasmid DNA Manufacturing Market, By Workflow

9.1. Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2024-2033

9.1.1. Upstream Manufacturing

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Downstream Manufacturing

9.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Viral Vector and Plasmid DNA Manufacturing Market, By Application 

10.1. Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2024-2033

10.1.1. Antisense & RNAi Therapy

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Gene Therapy

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Cell Therapy

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Vaccinology

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Research Applications

10.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Viral Vector and Plasmid DNA Manufacturing Market, By End-use

11.1. Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2024-2033

11.1.1. Pharmaceutical and Biopharmaceutical Companies

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Research Institutes

11.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Viral Vector and Plasmid DNA Manufacturing Market, By Disease

12.1. Viral Vector and Plasmid DNA Manufacturing Market, by Disease, 2024-2033

12.1.1. Cancer

12.1.1.1. Market Revenue and Forecast (2021-2033)

12.1.2. Genetic Disorders

12.1.2.1. Market Revenue and Forecast (2021-2033)

12.1.3. Infectious Diseases

12.1.3.1. Market Revenue and Forecast (2021-2033)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 13. Global Viral Vector and Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.1.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.1.3. Market Revenue and Forecast, by Application (2021-2033)

13.1.4. Market Revenue and Forecast, by End-use (2021-2033)

13.1.5. Market Revenue and Forecast, by Disease (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.1.6.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.1.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.1.6.4. Market Revenue and Forecast, by End-use (2021-2033)

13.1.7. Market Revenue and Forecast, by Disease (2021-2033) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.1.8.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.1.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.1.8.4. Market Revenue and Forecast, by End-use (2021-2033)

13.1.8.5. Market Revenue and Forecast, by Disease (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.2.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.2.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.4. Market Revenue and Forecast, by End-use (2021-2033) 

13.2.5. Market Revenue and Forecast, by Disease (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.2.6.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.2.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.7. Market Revenue and Forecast, by End-use (2021-2033) 

13.2.8. Market Revenue and Forecast, by Disease (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.2.9.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.2.9.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.10. Market Revenue and Forecast, by End-use (2021-2033)

13.2.11. Market Revenue and Forecast, by Disease (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.2.12.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.2.12.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.12.4. Market Revenue and Forecast, by End-use (2021-2033)

13.2.13. Market Revenue and Forecast, by Disease (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.2.14.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.2.14.3. Market Revenue and Forecast, by Application (2021-2033)

13.2.14.4. Market Revenue and Forecast, by End-use (2021-2033)

13.2.15. Market Revenue and Forecast, by Disease (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.3.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.3.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.4. Market Revenue and Forecast, by End-use (2021-2033)

13.3.5. Market Revenue and Forecast, by Disease (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.3.6.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.3.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.6.4. Market Revenue and Forecast, by End-use (2021-2033)

13.3.7. Market Revenue and Forecast, by Disease (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.3.8.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.3.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.8.4. Market Revenue and Forecast, by End-use (2021-2033)

13.3.9. Market Revenue and Forecast, by Disease (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.3.10.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.3.10.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.10.4. Market Revenue and Forecast, by End-use (2021-2033)

13.3.10.5. Market Revenue and Forecast, by Disease (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.3.11.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.3.11.3. Market Revenue and Forecast, by Application (2021-2033)

13.3.11.4. Market Revenue and Forecast, by End-use (2021-2033)

13.3.11.5. Market Revenue and Forecast, by Disease (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.4.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.4.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.4. Market Revenue and Forecast, by End-use (2021-2033)

13.4.5. Market Revenue and Forecast, by Disease (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.4.6.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.4.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.6.4. Market Revenue and Forecast, by End-use (2021-2033)

13.4.7. Market Revenue and Forecast, by Disease (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.4.8.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.4.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.8.4. Market Revenue and Forecast, by End-use (2021-2033)

13.4.9. Market Revenue and Forecast, by Disease (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.4.10.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.4.10.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.10.4. Market Revenue and Forecast, by End-use (2021-2033)

13.4.10.5. Market Revenue and Forecast, by Disease (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.4.11.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.4.11.3. Market Revenue and Forecast, by Application (2021-2033)

13.4.11.4. Market Revenue and Forecast, by End-use (2021-2033)

13.4.11.5. Market Revenue and Forecast, by Disease (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.5.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.5.3. Market Revenue and Forecast, by Application (2021-2033)

13.5.4. Market Revenue and Forecast, by End-use (2021-2033)

13.5.5. Market Revenue and Forecast, by Disease (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.5.6.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.5.6.3. Market Revenue and Forecast, by Application (2021-2033)

13.5.6.4. Market Revenue and Forecast, by End-use (2021-2033)

13.5.7. Market Revenue and Forecast, by Disease (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Vector Type (2021-2033)

13.5.8.2. Market Revenue and Forecast, by Workflow (2021-2033)

13.5.8.3. Market Revenue and Forecast, by Application (2021-2033)

13.5.8.4. Market Revenue and Forecast, by End-use (2021-2033)

13.5.8.5. Market Revenue and Forecast, by Disease (2021-2033)

Chapter 14. Company Profiles

14.1. Merck KGaA

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Lonza

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. FUJIFILM Diosynth Biotechnologies

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Thermo Fisher Scientific

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Cobra Biologics

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Catalent Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Wuxi Biologics

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Takara Bio Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Waisman Biomanufacturing

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Genezen laboratories

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms